IL-33 isoforms: Their future as vaccine adjuvants?

Expert Review of Vaccines

Volumn 14, Issue 4, 2015, Pages 489-492

  Villarreal, Daniel O ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adjuvant; cancer vaccine; CD8 T cell; cytokine; DNA vaccine; IL 33; immunotherapies; isoform

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; VACCINE; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; ISOPROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HELPER CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS INFECTION; GENETICS; HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; TRENDS;

ADJUVANTS, IMMUNOLOGIC; BIOMEDICAL RESEARCH; HUMANS; INTERLEUKIN-33; INTERLEUKINS; PROTEIN ISOFORMS; VACCINES;

EID: 84924353713     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1011135     Document Type: Review

References (23)

1. Vacchelli E, Aranda F, Obrist F, et al. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014;3: e29030
2. Commins SP, Borish L, Steinke JW. Immunolgic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 2010;125(2 Suppl 2):S53-72
3. Garcia-Blanco MA. Messanger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest 2003;271:23055-60
4. Whitaker EL, Filippov V, Filippova M, et al. Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells. Cytokine 2011;56: 272-81
5. Vudattu NK, Magalhaes I, Hoehn H, et al. Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun 2009;10:132-40
6. Hong J, Bae S, Jhun H, et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem 2011; 286(22):20078-86
7. Tsuda H, Komine M, Karakawa M, et al. Novel splice variants of IL-33: differential expression in normal and transformed cells. J Invest Dermatol 2012;132(11):2661-4
8. Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 2012;109: 1673-8
9. Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 2014;28:102-6
10. Le H, Kim W, Kim J, et al. Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front Immunol 2013;4:104
11. Yang Q, Li G, Zhu Y, et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8(+) T cells. Eur J Immunol 2011;41:3351-60
12. Ngoi SM, St Rose MC, Menoret AM, et al. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci USA 2012;109: 10486-91
13. Bonilla WV, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cells responses. Science 2012;335:984-9
14. Villarreal DO, Wise MC, Walters JN, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014;74(6): 1789-800
15. Martin M. Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 2013;25(6): 449-57
16. Luzina IG, Pickering EM, Kopach P, et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012;189:403-10
17. Wang L, Li H, Liang F, et al. Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-y. Med Oncol 2014;31:143
18. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046-55
19. Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012;52(1-2):89-99
20. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20(6):791-800
21. Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009;183(10): 6469-77
22. Price AE, Liang HE, Sullivan BM, et al. Systemicaly dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010;107:1055-62
23. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function. Nature 2014; 513(7519):564-8